Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients

Epilepsy Research

Volumn 71, Issue 1, 2006, Pages 54-63

  Argikar, Upendra A ^a   Cloyd, James C ^a   Birnbaum, Angela K ^a   Leppik, Ilo E ^a,b,c   Conway, Jeannine ^a   Kshirsagar, Smita ^a   Oetting, William S ^b   Klein, Erin C ^a   Remmel, Rory P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MINCEP Epilepsy Care   (United States)

Author keywords

Antiepileptic drug; CYP2C19; CYP2C9; Metabolism; p Hydroxyphenyl phenylhydantoin; Phenytoin; Polymorphisms

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DRUG METABOLITE; PHENYTOIN; PHENYTOIN DERIVATIVE;

ANTICONVULSANT THERAPY; ARTICLE; CHIRAL CHROMATOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG URINE LEVEL; EPILEPSY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC PROCEDURES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; URINALYSIS;

ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENOTYPE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; MUTATION; PHENYTOIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; STEREOISOMERISM;

EID: 33747156084     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2006.05.015     Document Type: Article

References (35)

1. Allabi A.C., Gala J.L., and Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet. Genom. 15 (2005) 779-786
2. Aynacioglu A.S., Brockmoller J., Bauer S., Sachse C., Guzelbey P., Ongen Z., Nacak M., and Roots I. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol. 48 (1999) 409-415
3. Bajpai M., Roskos L.K., Shen D.D., and Levy R.H. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos. 24 (1996) 1401-1403
4. Bhasker C.R., Miners J.O., Coulter S., and Birkett D.J. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 7 (1997) 51-58
5. Browne T.R., and Leduc B. Phenytoin and other hydantoins: chemistry and biotransformation. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Anti-epileptic Drugs. fifth ed. (2002), Lippincott Williams and Wilkins, Philadelphia 565-580
6. de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., and Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269 (1994) 15419-15422
7. De Morais S.M., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., and Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46 (1994) 594-598
8. Desta Z., Zhao X., Shin J.G., and Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41 (2002) 913-958
9. Dickinson R.G., Hooper W.D., Patterson M., Eadie M.J., and Maguire B. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther. Drug Monit. 7 (1985) 283-289
10. Dill W.A., Glazko A.J., Kazenko A., and Wolf L.M. Studies on 5,5′-diphenylhydantoin (dilantin) in animals and man. J. Pharmacol. Exp. Ther. 118 (1956) 270-279
11. Doecke C.J., Veronese M.E., Pond S.M., Miners J.O., Birkett D.J., Sansom L.N., and McManus M.E. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br. J. Clin. Pharmacol. 31 (1991) 125-130
12. Finta C., and Zaphiropoulos P.G. The human CYP2C locus: a prototype for intergenic and exon repetition splicing events. Genomics 63 (2000) 433-438
13. Fritz S., Lindner W., Roots I., Frey B.M., and Kupfer A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J. Pharmacol. Exp. Ther. 241 (1987) 615-622
14. Giancarlo G.M., Venkatakrishnan K., Granda B.W., von Moltke L.L., and Greenblatt D.J. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur. J. Clin. Pharmacol. 57 (2001) 31-36
15. Goldstein J.A., and Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol. 272 (1996) 210-218
16. Hashimoto Y., Otsuki Y., Odani A., Takano M., Hattori H., Furusho K., and Iui K. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Biol. Pharm. Bull. 19 (1996) 1103-1105
17. Hermansson J., Iversen T., and Lindquist U. Isolation and determination of the diastereomers of the glucuronidated 5-(4-hydroxyphenyl)-5-phenylhydantoin in human urine using HPLC. Acta Pharm. Suec. 19 (1982) 199-210
18. Hvidberg E.F. Ethnic differences in phenytoin kinetics. Prog. Clin. Biol. Res. 214 (1986) 279-287
19. Ieiri I., Mamiya K., Urae A., Wada Y., Kimura M., Irie S., Amamoto T., Kubota T., Yoshioka S., Nakamura K., Nakano S., Tashiro N., and Higuchi S. Stereoselective 4′-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese. Br. J. Clin. Pharmacol. 43 (1997) 441-445
20. Imai J., Ieiri I., Mamiya K., Miyahara S., Furuumi H., Nanba E., Yamane M., Fukumaki Y., Ninomiya H., Tashiro N., Otsubo K., and Higuchi S. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 10 (2000) 85-89
21. Kidd R.S., Straughn A.B., Meyer M.C., Blaisdell J., Goldstein J.A., and Dalton J.T. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9 (1999) 71-80
22. Lee C.R., Goldstein J.A., and Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12 (2002) 251-263
23. Livak K.J. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet. Anal. 14 (1999) 143-149
24. Mamiya K., Ieiri I., Shimamoto J., Yukawa E., Imai J., Ninomiya H., Yamada H., Otsubo K., Higuchi S., and Tashiro N. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39 (1998) 1317-1323
25. Odani A., Hashimoto Y., Takayanagi K., Otsuki Y., Koue T., Takano M., Yasuhara M., Hattori H., Furusho K., and Inui K. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biol. Pharm. Bull. 19 (1996) 444-448
26. Odani A., Hashimoto Y., Otsuki Y., Uwai Y., Hattori H., Furusho K., and Inui K. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin. Pharmacol. Ther. 62 (1997) 287-292
27. Smith G., Stubbins M.J., Harries L.W., and Wolf C.R. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 28 (1998) 1129-1165
28. Stubbins M.J., Harries L.W., Smith G., Tarbit M.H., and Wolf C.R. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6 (1996) 429-439
29. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., Zhang Z.Y., Kaminsky L.S., Shenfield G.M., Miners J.O., Birkett D.J., and Goldstein J.A. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6 (1996) 341-349
30. Taguchi M., Hongou K., Yagi S., Miyawaki T., Takizawa M., Aiba T., and Hashimoto Y. Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients. Drug Metab. Pharmacokinet. 20 (2005) 107-112
31. Tassaneeyakul W., Birkett D.J., Pass M.C., and Miners J.O. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo. Br. J. Clin. Pharmacol. 42 (1996) 774-778
32. Veronese M.E., Mackenzie P.I., Doecke C.J., McManus M.E., Miners J.O., and Birkett D.J. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun. 175 (1991) 1112-1118
33. Watanabe M., Iwahashi K., Kugoh T., and Suwaki H. Phenytoin kinetics in Japanese adult epileptics: phenotype of phenytoin slow metabolizers. Clin. Neuropharmacol. 20 (1997) 346-351
34. Watanabe M., Iwahashi K., Kugoh T., and Suwaki H. The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients. Clin. Neuropharmacol. 21 (1998) 122-126
35. Xie H.G., Prasad H.C., Kim R.B., and Stein C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54 (2002) 1257-1270